CytoDyn’s Leronlimab Prevents Transmission of SHIV in Macaque Study

Nachrichtenquelle: globenewswire
07.07.2020, 23:02  |  769   |   |   

Results of preclinical study presented today in oral presentation at the 23rd International AIDS Conference (AIDS 2020) 

VANCOUVER, Washington, July 07, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential clinical indications for HIV, COVID-19, cancer, GvHD and NASH announced today the results from a preclinical macaque study evaluating leronlimab as pre-exposure prophylaxis (PrEP) to prevent sexual HIV transmission. The study evaluated the impact of a macaque-equivalent dose of either 350 mg (once weekly) or 700 mg (bi-monthly) leronlimab on acquisition of infection in a total of 18 animals, and found that the equivalent 700 mg bi-monthly leronlimab dose completely prevented rectal transmission of Simian-Human Immunodeficiency Virus (SHIV) in macaques. These results were presented today in an oral presentation titled “CCR5 antibody blockade protects rhesus macaques from rectal SHIV acquisition" at the 23rd International AIDS Conference (AIDS 2020).

“The results reported here in the preclinical macaque model of HIV sexual transmission support leronlimab as a possible PrEP agent at a time when long-acting human HIV PrEP options are limited,” said Dr. Jonah Sacha, Professor at Oregon Health & Science University, and the study’s lead investigator.

“We are eager to build upon these preclinical results describing leronlimab’s utility in HIV prevention by initiating clinical studies for leronlimab as a PrEP treatment. Current PrEP options require a continued daily dosing regimen in order to be effective and are inherently difficult to maintain in the long-term,” said Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn. “Coupled with its safety profile, leronlimab could offer a much needed simple and long-lasting preventative treatment option for people at risk of HIV infection,” concluded Dr. Pourhassan.

About Coronavirus Disease 2019
CytoDyn has met its 75-patient enrollment target in its Phase 2 clinical trial for COVID-19, a randomized clinical trial for mild-to-moderate COVID-19 population in the U.S. and enrollment continues in its Phase 2b/3 randomized clinical trial for severe and critically ill COVID-19 population in several hospitals throughout the country.

SARS-CoV-2 was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China. The origin of SARS-CoV-2 causing the COVID-19 disease is uncertain, and the virus is highly contagious. COVID-19 typically transmits person to person through respiratory droplets, commonly resulting from coughing, sneezing, and close personal contact. Coronaviruses are a large family of viruses, some causing illness in people and others that circulate among animals. For confirmed COVID-19 infections, symptoms have included fever, cough, and shortness of breath. The symptoms of COVID-19 may appear in as few as two days or as long as 14 days after exposure. Clinical manifestations in patients have ranged from non-existent to severe and fatal. At this time, there are minimal treatment options for COVID-19.

Seite 1 von 5
Cytodyn Aktie jetzt ab 0€ handeln - auf Smartbroker.de



Diesen Artikel teilen

0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Meistgelesene Nachrichten des Autors

Titel
Titel
Titel
Titel

Diskussionen zu den Werten

ZeitTitel
01:09 Uhr